AR063011A1 - Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico - Google Patents
Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermicoInfo
- Publication number
- AR063011A1 AR063011A1 ARP070104260A ARP070104260A AR063011A1 AR 063011 A1 AR063011 A1 AR 063011A1 AR P070104260 A ARP070104260 A AR P070104260A AR P070104260 A ARP070104260 A AR P070104260A AR 063011 A1 AR063011 A1 AR 063011A1
- Authority
- AR
- Argentina
- Prior art keywords
- therapy
- growth factor
- epidermal growth
- therapeutic compositions
- receiver
- Prior art date
Links
- 102000009024 Epidermal Growth Factor Human genes 0.000 title abstract 3
- 101800003838 Epidermal growth factor Proteins 0.000 title abstract 3
- 229940116977 epidermal growth factor Drugs 0.000 title abstract 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 230000000694 effects Effects 0.000 title 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 229940047124 interferons Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invencion describe composiciones terapéuticas específicas, que aumentan la eficacia de la terapia con anticuerpos monoclonales (AcMs)contra el receptor del Factor de Crecimiento Epidérmico (EGFR, del inglés "epidermal growth factor receptor") e interferones (INFs de tipo I (alfa/beta).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20060190A CU23612A1 (es) | 2006-09-29 | 2006-09-29 | Combinaciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR063011A1 true AR063011A1 (es) | 2008-12-23 |
Family
ID=40223744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070104260A AR063011A1 (es) | 2006-09-29 | 2007-09-26 | Composiciones terapeuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidermico |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20100047207A1 (es) |
| EP (1) | EP2070547B1 (es) |
| KR (1) | KR101482957B1 (es) |
| CN (2) | CN101678099A (es) |
| AR (1) | AR063011A1 (es) |
| AU (1) | AU2007302429B2 (es) |
| BR (1) | BRPI0717142A2 (es) |
| CA (1) | CA2664795C (es) |
| CL (1) | CL2007002797A1 (es) |
| CO (1) | CO6160338A2 (es) |
| CR (1) | CR10753A (es) |
| CU (1) | CU23612A1 (es) |
| MA (1) | MA30811B1 (es) |
| MX (1) | MX2009003159A (es) |
| PE (1) | PE20080674A1 (es) |
| TN (1) | TN2009000104A1 (es) |
| TR (1) | TR200902344T1 (es) |
| UY (1) | UY30616A1 (es) |
| WO (1) | WO2008037225A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009152783A1 (es) * | 2008-06-20 | 2009-12-23 | Centro De Inmunologia Molecular | Inhibidores del receptor del factor de crecimiento epidérmico (egfr) con acción citostática y sus usos en la terapia de tumores |
| CN103536917B (zh) * | 2013-10-30 | 2015-03-11 | 苏州丁孚靶点生物技术有限公司 | 干扰素在治疗肿瘤中的用途及相关的产品和方法 |
| MY203111A (en) * | 2015-07-27 | 2024-06-10 | Oncoscience Ag | Treatment of patients diagnosed with pancreatic ductal adenocarcinomra using monoclonal antibodies against the epidermal growth factor receptor (egfr) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| RU2129437C1 (ru) * | 1992-02-10 | 1999-04-27 | Интерферон Сайнс Инк. | Композиция альфа-интерферона и способ ее получения из лейкоцитов крови человека |
| US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
| US6949520B1 (en) * | 1999-09-27 | 2005-09-27 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
| CA2449166A1 (en) * | 2001-05-08 | 2002-11-14 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Combination therapy using anti-egfr antibodies and anti-hormonal agents |
| US20060134064A1 (en) * | 2004-12-20 | 2006-06-22 | David Goldstein | Combined treatment with interferon-alpha and an epidermal growth factor receptor kinase inhibitor |
| US20110189178A1 (en) * | 2010-02-04 | 2011-08-04 | Xencor, Inc. | Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions |
-
2006
- 2006-09-29 CU CU20060190A patent/CU23612A1/es unknown
-
2007
- 2007-09-26 AR ARP070104260A patent/AR063011A1/es unknown
- 2007-09-27 CN CN200780036290A patent/CN101678099A/zh active Pending
- 2007-09-27 KR KR1020097007699A patent/KR101482957B1/ko not_active Expired - Fee Related
- 2007-09-27 BR BRPI0717142-0A patent/BRPI0717142A2/pt not_active IP Right Cessation
- 2007-09-27 WO PCT/CU2007/000017 patent/WO2008037225A1/es not_active Ceased
- 2007-09-27 CA CA2664795A patent/CA2664795C/en not_active Expired - Fee Related
- 2007-09-27 CL CL200702797A patent/CL2007002797A1/es unknown
- 2007-09-27 CN CN2012104701143A patent/CN102940883A/zh active Pending
- 2007-09-27 US US12/442,608 patent/US20100047207A1/en not_active Abandoned
- 2007-09-27 PE PE2007001310A patent/PE20080674A1/es not_active Application Discontinuation
- 2007-09-27 AU AU2007302429A patent/AU2007302429B2/en not_active Ceased
- 2007-09-27 EP EP07817381.2A patent/EP2070547B1/en not_active Not-in-force
- 2007-09-27 TR TR2009/02344T patent/TR200902344T1/xx unknown
- 2007-09-27 MX MX2009003159A patent/MX2009003159A/es active IP Right Grant
- 2007-09-28 UY UY30616A patent/UY30616A1/es not_active Application Discontinuation
-
2009
- 2009-03-25 CO CO09030399A patent/CO6160338A2/es unknown
- 2009-03-27 TN TN2009000104A patent/TN2009000104A1/fr unknown
- 2009-04-23 MA MA31815A patent/MA30811B1/fr unknown
- 2009-04-29 CR CR10753A patent/CR10753A/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0717142A2 (pt) | 2013-10-15 |
| EP2070547A4 (en) | 2011-11-02 |
| WO2008037225A1 (es) | 2008-04-03 |
| CU23612A1 (es) | 2010-12-08 |
| CL2007002797A1 (es) | 2008-04-18 |
| CO6160338A2 (es) | 2010-05-20 |
| US20100047207A1 (en) | 2010-02-25 |
| CA2664795A1 (en) | 2008-04-03 |
| MX2009003159A (es) | 2009-04-06 |
| KR20090058566A (ko) | 2009-06-09 |
| UY30616A1 (es) | 2008-05-02 |
| CN102940883A (zh) | 2013-02-27 |
| EP2070547B1 (en) | 2013-04-24 |
| MA30811B1 (fr) | 2009-10-01 |
| TR200902344T1 (tr) | 2009-08-21 |
| KR101482957B1 (ko) | 2015-01-15 |
| CA2664795C (en) | 2014-06-17 |
| EP2070547A1 (en) | 2009-06-17 |
| AU2007302429A1 (en) | 2008-04-03 |
| PE20080674A1 (es) | 2008-07-23 |
| CN101678099A (zh) | 2010-03-24 |
| AU2007302429B2 (en) | 2013-10-03 |
| TN2009000104A1 (en) | 2010-08-19 |
| CR10753A (es) | 2009-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY30525A1 (es) | Agentes de union dirigidos cuyo blanco es el pdgfr-alfa y sus usos | |
| CO2022002622A2 (es) | Anticuerpos anti-cd73 y composiciones | |
| GT201400057A (es) | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante | |
| CY1114872T1 (el) | Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης | |
| PA8846101A1 (es) | Anticuerpos del receptor ii anti-tgf-beta | |
| UY33222A (es) | Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas | |
| CO6450656A2 (es) | Anticuerpos anti-tnf-alfa y sus usos | |
| BRPI0911031B8 (pt) | compostos de piperidina ligada do tipo quinoxalina substituídos e os usos destes | |
| AR063760A1 (es) | Anticuerpos anti-factor d humanizados y usos de los mismos | |
| GT201200258A (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| BR112013032717A2 (pt) | coagonistas do receptor de glucagon/glp-1 | |
| BR112012019098B8 (pt) | anticorpo, composição farmacêutica, combinação farmacêutica e usos de um anticorpo, de uma composição farmacêutica e de uma combinação farmacêutica | |
| NZ607996A (en) | Substituted nucleotide analogs | |
| GT201200189A (es) | Antagonistas de pcsk9 | |
| ECSP10010637A (es) | Anticuerpos anti-factor d humanizados y sus usos | |
| PA8772101A1 (es) | Imidazol-triazolopirimidinas sustituidas | |
| MX2019013690A (es) | Conjugados de farmaco-proteina con ciclodextrina. | |
| CR10309A (es) | "compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1" | |
| CL2009000402A1 (es) | Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras. | |
| CR20120508A (es) | PROTEÍNA DE FUSIÓN ROBO1-Fc Y SU UTILIZACIÓN EN EL TRATAMIENTO DE TUMORES | |
| BR112012028445A2 (pt) | compostos de heteroarila bicíclica como moduladores de gpr119 | |
| BR112012021334A2 (pt) | material biodegradável, contendo silício, para terapia anti-inflamatória. | |
| GT200500187A (es) | Moduladores de andrògenos | |
| CO2023015212A2 (es) | Receptores quiméricos dirigidos a adgre2 y/o clec12a y usos de estos | |
| BR112022011957A2 (pt) | Composições e métodos de tratamento de câncer com receptores de antígenos quiméricos visando glipicana 3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |